Syros has built a proprietary gene control platform designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, we believe our gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of therapeutic areas and diseases.
Syros is focused on cancer and immune-mediated diseases, and we are building a pipeline of gene control medicines, including our two lead programs SY-1425, an oral, potent and selective RARa agonist that we are initially developing in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and SY-1365, a highly potent and selective CDK7 inhibitor that we are initially developing in certain solid tumors.
Using our platform, we are also generating a pipeline of novel drug candidates in earlier stages of research and development for genomically defined subsets of currently underserved patients.
At Syros, our mission of transforming patients’ lives guides our every goal and action. Our team lives our values of pioneering science, excellence, passion, integrity and respect as we strive to discover and develop a new wave of medicines that provide a profound and durable benefit for patients.
Our management team has a track record of translating scientific discoveries into innovative therapies in cancer, rare disease, neurology and immunology.
Researchers have long believed that alterations in non-coding regions of DNA, which account for 98% of the genome, play a key role in driving disease. However, the scientific community has lacked the tools to study these regions of the genome. As a result, targeted drug discovery and development to date has focused almost exclusively on genetic alterations found in regions of DNA that code for proteins, which represent less than 2% of the genome. Rapidly growing scientific evidence now points to non-coding regions of the genome as fundamental to cell type and function and to alterations in these regions as involved in the development and progression of a broad range of diseases.
While all cells share the same genome, each of the nearly 200 different cell types in the human body has a different function. What determines a cell’s type and function is the specific set of genes that is expressed, or turned ‘‘on’’ or ‘‘off,’’ in that particular cell. This coordinated activation and repression of genes is known as the cell’s gene expression program and it is controlled by non-coding regions of DNA. Alterations in these non-coding regions change a cell’s gene expression program, altering its normal function and leading to disease. Because this biology is fundamental to the function of all cells, it applies across diseases, whether the cause is genetic, environmental, bacterial, viral or multi-factorial.
Learn more about gene control
Syros is solely focused on gene control. Building on the seminal discoveries of our scientific founders, we have developed what we believe is the first proprietary platform designed to systematically and efficiently analyze non-coding regions of the genome to identify alterations in gene expression programs.
By doing so, we believe our gene control platform will allow us to:
Learn more about our platform
Syros is focused on discovering and developing treatments for cancer and immune-mediated diseases, and we are building a pipeline of gene control medicines that have the potential to provide a profound and durable benefit for currently underserved patients.
Learn more about our pipeline
Syros’ scientific founders have produced groundbreaking discoveries in gene control.
RICHARD YOUNG, PHD
Member, Whitehead Institute
Professor of Biology, Massachusetts Institute of Technology
World leader in regulatory circuitry that controls the gene expression programs in cells
JAY BRADNER, MD
President, Novartis Institutes for BioMedical Research (NIBR)
Attending Physician & Investigator, Department of Medical Oncology Dana-Farber Cancer Center
World leader in small-molecule modulation of gene regulatory pathways; pioneering work in the bromodomain area
NATHANAEL GRAY, PHD
Professor of Biological Chemistry & Molecular Pharmacology, Harvard Medical School | Dana-Farber Cancer Center
Pioneering use of synthetic chemistry and functional small molecule discovery to modulate biological pathways important in cancer; responsible for the discovery of numerous first-in-class kinase inhibitors